At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV ...

Gilead Sciences' leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be ...

Delve into the landscape of biotech companies developing treatments for HIV and find out if we are getting closer to a cure.

Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...

The Trump administration's cuts to HIV prevention will lead to new infections, medical costs and death, experts warn.

Gilead Sciences’ sponsorship of a conference Wi-Fi network has landed it in hot water. | Gilead Sciences’ sponsorship of a ...

In a sliding market, Gilead Sciences has defied the odds, trading up to $106.42 per share. Its 24% gain since October 2024 ...

Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...

Research in the Sundquist lab laid the foundations for the development of lenacapavir, a drug that prevents HIV infection ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Focused on elevating Abu Dhabi as a hub for groundbreaking medical research, the partnership aims to enhance treatment ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly effective medicine. However, Ben Hargreaves finds that the company’s ...